AQR Capital Management
RCUS icon

AQR Capital Management’s Arcus Biosciences RCUS Stock Holding History

AQR Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.86M Buy
86,294
+87
+0.1% +$1.88K ﹤0.01% 2398
2025
Q4 		$2.05M Buy
86,207
+2,430
+3% +$49.6K ﹤0.01% 2116
2025
Q3 		$1.14M Sell
83,777
-24,522
-23% -$255K ﹤0.01% 2351
2025
Q2 		$882K Buy
108,299
+17,345
+19% +$148K ﹤0.01% 2286
2025
Q1 		$714K Buy
90,954
+65,254
+254% +$757K ﹤0.01% 2227
2024
Q4 		$383K Sell
25,700
-390
-1% -$6.37K ﹤0.01% 2381
2024
Q3 		$399K Buy
26,090
+1,566
+6% +$24.7K ﹤0.01% 2268
2024
Q2 		$374K Buy
24,524
+9,916
+68% +$160K ﹤0.01% 2183
2024
Q1 		$276K Buy
14,608
+3,661
+33% +$63.3K ﹤0.01% 2157
2023
Q4 		$209K Buy
+10,947
New +$175K ﹤0.01% 2199
2023
Q2 		– Sell
-221,257
Closed -$4.04M – 2264
2023
Q1 		$4.04M Buy
221,257
+100,293
+83% +$1.92M 0.01% 988
2022
Q4 		$2.5M Buy
120,964
+856
+0.7% +$23.6K 0.01% 1165
2022
Q3 		$3.14M Buy
120,108
+49,775
+71% +$1.32M 0.01% 1007
2022
Q2 		$1.78M Buy
+70,333
New +$1.72M ﹤0.01% 1149
2021
Q4 		– Sell
-5,869
Closed -$205K – 2265
2021
Q3 		$205K Sell
5,869
-31,770
-84% -$989K ﹤0.01% 2148
2021
Q2 		$1.03M Sell
37,639
-9,587
-20% -$274K ﹤0.01% 1579
2021
Q1 		$1.33M Sell
47,226
-18,740
-28% -$652K ﹤0.01% 1427
2020
Q4 		$1.71M Buy
65,966
+526
+0.8% +$12.7K ﹤0.01% 1242
2020
Q3 		$1.12M Buy
65,440
+7,278
+13% +$163K ﹤0.01% 1364
2020
Q2 		$1.44M Buy
58,162
+32,186
+124% +$869K ﹤0.01% 1308
2020
Q1 		$361K Sell
25,976
-971
-4% -$12.1K ﹤0.01% 1696
2019
Q4 		$272K Buy
+26,947
New +$227K ﹤0.01% 1932

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

AQR Capital Management's RCUS Position: Q1 2026 in Review

AQR Capital Management increased its Arcus Biosciences (RCUS) stake by 0.1% in Q1 2026, buying an estimated $1.88K and bringing the position to 86,294 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #2398.

AQR Capital Management first reported a position in RCUS in Q4 2019 and has held it in 22 quarters since. The position peaked at $4.04M in Q1 2023. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • AQR Capital Management held 86,294 shares of Arcus Biosciences worth $1.86M as of Q1 2026.
  • AQR Capital Management bought 87 Arcus Biosciences shares in Q1 2026, an estimated $1.88K.
  • Arcus Biosciences made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2398 holding.
  • AQR Capital Management first reported a position in Arcus Biosciences in Q4 2019 and has held it in 22 quarters since.
  • AQR Capital Management's Arcus Biosciences position peaked at $4.04M in Q1 2023.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.